Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers (Cell Chemical Biology)

The most common approach for pharmacokinetic enhancement of biologically inspired therapies is PEGylation; however, possible limitations of this formulation strategy have arisen. Here, we describe how anti-PEG antibodies can inhibit the therapeutic efficacy of a PEGylated RNA aptamer. These findings further highlight emerging issues between the immune system and PEGylated therapeutics.